Mechanism of action of leflunomide in rheumatoid arthritis

Journal of Rheumatology

Volumn 25, Issue SUPPL. 53, 1998, Pages 20-26

  Fox, Robert I ^a,b  

^a SCRIPPS CLINIC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Dihydroorotate dehydrogenase; Immunoregulation; Leflunomide; P53; Rheumatoid arthritis; Uridine

Indexed keywords

ADENOSINE TRIPHOSPHATE; AUTOANTIBODY; AZATHIOPRINE; CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING); CYCLINE; CYCLOSPORIN A; CYTOKINE; DIHYDROOROTATE DEHYDROGENASE; DNA; GLUTAMINE; LEFLUNOMIDE; METHOTREXATE; MITOGENIC AGENT; PHOSPHORIBOSYL PYROPHOSPHATE; PIRAZOFURIN; PROSTAGLANDIN SYNTHASE; PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE; RIBONUCLEOTIDE; SPARFOSIC ACID; TERIFLUNOMIDE; URIDINE; URIDINE PHOSPHATE; ANTIRHEUMATIC AGENT; ISOXAZOLE DERIVATIVE; OXIDOREDUCTASE;

CELL CYCLE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; REVIEW;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELL CYCLE; HUMANS; ISOXAZOLES; LYMPHOCYTE ACTIVATION; OXIDOREDUCTASES; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PROTEIN-TYROSINE KINASES;

EID: 0031865023     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996;8:710-20.
2. Leflunomide Investigator's Brochure. Weisbaden, Germany: Hoechst AG; March 1995.
3. Bartlett RR, Brendel S, Zielinski T, Schorlemmer HU. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplant Proc 1996;28:3074-8.
4. Silva HT, Morris RE. Leflunomide and malononitrilamides. Am J Med Sci 1997;313:289-301.
5. Chong AS, Rezai K, Gebel HM, et al. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996;61:140-5.
6. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A. Regulation of B-cell function by the immunosuppressive agent leflunomide. Transplantation 1996;61:635-42.
7. Silva HT Jr, Cao W, Shorthouse RA, Loffler M, Morris RE. In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. Transplant Proc 1997;29:1292-3.
8. Davis J, Cain G, Pitts W, Magolda R, Copeland R. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996;35:1270-3.
9. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995;50:861-7.
10. Zielinski T, Zeitter D, Muller S, Bartlett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflammation Res 1995;44 Suppl 2:S207-S208.
11. Xu X, Blinder L, Shen J, et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 1997;159:167-74.
12. Kuo EA, Hambleton PT, Kay DP, et al. Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl -3-hydroxy-N-[3′-methyl-4′-(trifluoromethyl)-phenyl] propenamide and related compounds. J Med Chem 1996;39:4608-21.
13. Knecht W, Bergjohann U, Gonski S, Kirschbaum B, Loffler M. Functional expression of a fragment of human dihydroorotate dehydrogenase by means of the baculovirus expression vector system, and kinetic investigation of the purified recombinant enzyme. Eur J Biochem 1996;240:292-301.
14. Silva HT, Cao W, Shorthouse R, Morris RE. Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation. Transplant Proc 1996;28:3082-4.
15. Cao W, Kao P, Chao A, Gardner P, Ng J, Morris R. Mechanism of the antiproliferative action of leflunomide. J Heart Lung Transplant 1995;14:1016-30.
16. Elder R, Xu X, Williams J, Gong H, Finnegan A, Chong A. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997;159:22-7.
17. Green DR, Scott DW. Activation-induced apoptosis in lymphocytes. Curr Opin Immunol 1994;6:476-87.
18. Wahl GM, Linke SP, Paulson T, Huang L. Maintaining genetic stability through akp53-mediated checkpoint control. Cancer Surv 1997; (In Press).
19. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996;10:934-47.
20. Linke SP, Clarkin KC, Wahl GM. p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res 1997;57:1171-9.
21. Fox R, Morris R. Treatment of autoimmune disorders using inhibitors of pyrimidine synthesis. In: Strand V, Scott D, Simon L, editors. Therapeutic agents for treatment of autoimmune disease. New York: Marcel Dekker; 1996:257-87.
22. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-9.
23. Cherwinski HM, McCarley D, Schatzman R, Devens B, Ransom JT. The immunosuppressant leflunomide inhibits lymphocyte proliferation by a novel mechanism. J Pharmacol Exp Ther 1995;272:1043-9.
24. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995;38:1595-603.
25. Di Leonardo A, Linke S, Yin Y, Wahl G. Cell cycle regulation of gene amplification. Cold Spring Harbor Symposium Quant Biol 1993;58:655-67.
26. Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs 1994;47:25-50.
27. Zhang X, Brunner T, Carter L, et al. Unequal death in T-helper cells (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997;185:1837-49.
28. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995;270:29682-9.
29. Theofilopoulos AN. The basis of autoimmunity: I. Mechanisms of aberrant self-recognition. Immunol Today 1995;16:90-8.
30. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T-cell apoptosis in the rheumatoid synovium. J Clin Invest 1997;99:439-46.
31. Akbar AN, Salmon M. Cellular environments and apoptosis: Tissue microenvironments control activated T cell death. Immunol Today 1997;18:72-6.
32. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995;96:1631-8.
33. Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol 1996;149:2143-51.
34. Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc 1996;28:3086-7.
35. Yeh LS, Gregory CR, Griffey SM, Lecouteur RA, Morris RE. Effects of leflunomide and cyclosporine on myocutaneous allograft survival in the rat. Transplantation 1996;62:861-3.
36. Jalkanen S, Steere AC, Fox RI, Butcher EC. A distinct endothelial cell recognition system controlling lymphocyte traffic into inflamed synovium. Science 1986;233:556-9.
37. Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 1997;99:2165-72.
38. Pilkington C, Yeung E, Isenberg D, Lefvert AK, Rook GA. Agalactosyl IgG and antibody specificity in rheumatoid arthritis, tuberculosis, systemic lupus erythematosus and myasthenia gravis. Autoimmunity 1995;22:107-11.
39. Cao WW, Kao PN, Aoki Y, Xu JC, Shorthouse RA, Morris RE. A novel mechanism of action of the immunoregulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996;28:3079-80.
40. Hamilton L, Vojnovic I, Bakhle Y, Warner T, Vane J. The antiinflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 more potently than the induction of COX-2 or iNOS [abstract]. Br J Pharmacol 1997;120 Suppl:S49.